Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Washington University School of Medicine is running a randomized Phase 1 trial (active, not recruiting) of optimized neoantigen synthetic long peptide (SLP) vaccines co-administered with poly-ICLC in pancreatic cancer patients following neoadjuvant chemotherapy. The two arms test sequencing directly: vaccination after surgery versus vaccination in the window prior to surgery, while the tumor is still in place. Patients whose vaccine was manufactured but who progress on chemo or cannot complete resection may still receive injections on study. For a tumor type where vaccine development is difficult, the window-versus-post-surgery randomization is a low-cost sequencing question with implications for how the whole field schedules dosing around resection.